Cochrane · systematic review · CD012918
Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis
Grace, AG, Mittal, A, Jain, S, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
10
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 10%Low 1 · 10%Moderate 8 · 80%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Moxifloxacin‐containing 4‐month ATT regimens versus standard 6‐month ATT regimen for drug‐sensitive pulmonary tuberculosis
Population: adults with drug‐sensitive pulmonary tuberculosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relapse Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen | RR 3.56 [2.37, 5.37] | 3 studies · 2265 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Death from any cause Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen | RR 1.06 [0.65, 1.75] | 3 studies · 2760 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Treatment failure Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen | RR 0.71 [0.33, 1.52] | 3 studies · 2282 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Acquired drug resistance Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen | RR 0.33 [0.08, 1.31] | 3 studies · 2282 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Serious adverse events Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen | RR 0.97 [0.74, 1.27] | 4 studies · 3548 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Gatifloxacin‐containing 4‐month ATT regimens compared to standard 6‐month ATT regimens for drug‐sensitive pulmonary tuberculosis
Population: adults with drug‐sensitive pulmonary tuberculosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relapse Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimens | RR 2.11 [1.56, 2.84] | 2 studies · 1633 participants | Moderate Downgraded: risk of bias, imprecision, indirectness |
Death from any cause Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimens | RR 0.9 [0.53, 1.53] | 2 studies · 1886 participants | Moderate Downgraded: risk of bias, imprecision, indirectness |
Treatment failure Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimens | RR 0.93 [0.51, 1.7] | 2 studies · 1657 participants | Moderate Downgraded: risk of bias, imprecision, indirectness |
Acquired drug resistance Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimens | RR 0.24 [0.01, 5.01] | 1 study · 301 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimens | RR 1.02 [0.58, 1.77] | 2 studies · 1993 participants | Moderate Downgraded: risk of bias, imprecision, indirectness |